78D Stock Chart & Stats
€0.05
<€0.01(1.56%)
At close: 4:00 PM EST
€0.05
<€0.01(1.56%)
Day’s Range― - ―
52-Week Range€0.01 - €0.24
Previous CloseN/A
Volume0.00
Average Volume (3M)321.00
Market Cap
€12.05M
Enterprise Value€66.43
Total Cash (Recent Filing)€13.31M
Total Debt (Recent Filing)€800.00K
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding324,224,880
10 Day Avg. Volume964
30 Day Avg. Volume321
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-2.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Alzheimer’s TechnologyA focused, proprietary approach to amyloid-beta oligomers gives Alzinova a differentiated scientific platform in Alzheimer’s disease. If development succeeds, this technology could support multiple candidates, strengthen partnering potential, and create longer-term intellectual-property value.
Very Low LeverageMinimal debt materially reduces financial risk and limits interest-related pressure while the company funds research and development. This conservative capital structure provides greater flexibility to direct available resources toward clinical programs rather than debt service.
Potential Partnering ModelA partnering-oriented model can provide a path to future upfront, milestone, and royalty income without requiring Alzinova to fund every development and commercial activity alone. Successful partnerships could broaden resources and improve the economic scalability of its pipeline.
Bears Say
Persistent Operating LossesDeeply negative operating profit and net income show that Alzinova remains far from breakeven and has not yet converted its research platform into sustainable earnings. Continued losses may constrain strategic flexibility and require ongoing funding while candidates remain in development.
Ongoing Cash BurnNegative operating and free cash flow indicate that current activities consume cash rather than generate it. The company therefore remains dependent on external funding to sustain operations and investment, while deteriorating free cash flow increases pressure on future financing decisions.
Volatile And Declining RevenueLow and inconsistent revenue provides limited evidence of a durable commercial base, especially relative to the company’s substantial research expenses. Revenue volatility makes internal funding less predictable and leaves future financial performance heavily dependent on pipeline progress or partnering outcomes.
78D FAQ
What was Alzinova AB’s price range in the past 12 months?
Alzinova AB lowest stock price was €0.01 and its highest was €0.24 in the past 12 months.
What is Alzinova AB’s market cap?
Alzinova AB’s market cap is €12.05M.
When is Alzinova AB’s upcoming earnings report date?
Alzinova AB’s upcoming earnings report date is Nov 12, 2026 which is in 46 days.
How were Alzinova AB’s earnings last quarter?
Alzinova AB released its earnings results on Aug 20, 2026. The company reported -€0.003 earnings per share for the quarter.
Is Alzinova AB overvalued?
According to Wall Street analysts Alzinova AB’s price is currently Overvalued.
Does Alzinova AB pay dividends?
Alzinova AB does not currently pay dividends.
What is Alzinova AB’s EPS estimate?
Alzinova AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alzinova AB have?
Alzinova AB has 324,224,880 shares outstanding.
What happened to Alzinova AB’s price movement after its last earnings report?
Alzinova AB reported an EPS of -€0.003 in its last earnings report. Following the earnings report the stock price went down -3.125%.
Which hedge fund is a major shareholder of Alzinova AB?
Currently, no hedge funds are holding shares in DE:78D
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alzinova AB
Alzinova AB (publ) is a Swedish biotechnology company dedicated to advancing novel immunotherapies against Alzheimer's disease. Their primary investigational product, ALZ-101, is a vaccine specifically designed to target oligomers responsible for Alzheimer's. Additionally, they are developing ALZ-201, a monoclonal antibody aimed at neutralizing harmful amyloid-beta (Aß) oligomers. Established in 2011, the company's operations are headquartered in Mölndal, Sweden.
Technical Analysis
AlzeCure Pharma AB
―
BioArctic AB Class B
―
Saniona AB
―
IRLAB Therapeutics AB Class A
―
Active Biotech AB
―